• Meropenem: From PBP Action to Resistance Mapping

  2026-09-15

  Meropenem is a β-lactam antibiotic carbapenem whose value in research extends beyond susceptibility testing. This article connects PBP pharmacology with plasmid transmission, helping researchers design more interpretable assays for carbapenem-resistant bacterial infections and Gram-negative infection models.

• Aurora A in Retinoblastoma: Evidence for Targeted Therapy

  2026-09-15

  A 2024 American Journal of Pathology study identifies AURKA overexpression as a recurrent feature of human retinoblastoma and links it to histopathologic indicators of high-risk disease. By combining patient-tissue analysis with genetic and pharmacologic perturbation in cellular, patient-derived, and xenograft models, the work supports AURKA as a candidate vulnerability while defining its relationship with MYCN.

• tFUS Suppresses Stroke Neuroinflammation via SHP2

  2026-09-14

  This study identifies the Nespas/miR-383-3p/SHP2 axis as a mechanistic link between low-intensity transcranial focused ultrasound stimulation and suppression of NLRP3-mediated neuroinflammation after ischemic stroke. Rat and BV2 microglial experiments connect tFUS treatment with improved neurological outcomes, reduced infarction, and lower inflammasome activation, while also defining experimental entry points for studying SHP2-dependent microglial responses.

• Meropenem: Mechanism to Resistance Strategy

  2026-09-14

  A translational perspective on Meropenem that connects PBP-targeted bactericidal activity with carbapenemase mobility, resistance-aware assay design, and strategic use in Gram-negative infection models.

• JNK-IN-7: Causal Mapping of Infection Apoptosis

  2026-09-13

  JNK-IN-7 is a selective JNK inhibitor for dissecting c-Jun signaling, pathogen-induced apoptosis, and innate immune responses. This article presents a phase-resolved assay strategy that separates MAPK pathway activity from downstream cell-death execution.

• Ertapenem Sodium Salt in Resistance Workflows

  2026-09-12

  Build a practical Ertapenem sodium salt workflow that links broth microdilution with carbapenemase detection, plasmid localization, and transfer analysis. The approach converts a broad-spectrum phenotype into evidence for antibiotic resistance research while clearly separating assay observations from clinical interpretation.

• Protease and Phosphatase Inhibitor Cocktail Workflow

  2026-09-11

  Protect protein abundance and phosphorylation states from the moment cells or tissues are disrupted. This EDTA-free, 100X formulation is especially useful for metal-sensitive signaling assays, phosphoprotein immunoblotting, organoid studies, and comparative proteomics.

• Cefoperazone Sodium Salt: Assay Logic

  2026-09-10

  Cefoperazone sodium salt is a β-lactam research tool for studying antibacterial activity, enzyme stability, and biliary tract infection models. This guide goes beyond compound description to show how comparator data, assay design, and formulation choices shape defensible experimental conclusions.

• PTT and CD47 Blockade in Oral Cancer

  2026-09-10

  A 2026 study shows that photothermal therapy (PTT) can strengthen CD47 blockade in oral squamous cell carcinoma by coupling calreticulin-dependent phagocytic signaling with extracellular matrix remodeling. The findings clarify why blocking a tumor cell “don’t eat me” signal may be insufficient without both an “eat me” cue and improved macrophage access.

• NAD+ Workflows for AMPK Energy-Stress Assays

  2026-09-09

  Build reproducible NAD+ assays that separate redox chemistry, enzyme activity, and autophagy signaling during energy stress. This workflow translates new AMPK–ULK1 findings into practical controls for metabolic, deacetylation, and inhibitor-design experiments.

• MK-4827: Functional PARP Sensitization Beyond BRCA

  2026-09-09

  MK-4827 (Niraparib) is a selective PARP-1/-2 inhibitor for dissecting DNA repair dependence in cancer research. This article develops a functional assay framework showing how BRCA2 protein state, hyperthermia, and orthogonal readouts can reveal PARP inhibitor sensitivity beyond fixed BRCA genotype.

• Baicalin Methyl Ester and Intestinal Barrier Repair

  2026-09-08

  A 2024 Biomedicine & Pharmacotherapy study shows that baicalin methyl ester attenuates LPS-induced intestinal barrier injury in mice and MODE-K epithelial cells. Its central contribution is the integration of P65 binding evidence with TNF-α, MLCK, and tight-junction measurements, linking inflammatory signaling to barrier restoration.

• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-09-08

  The 2025 study establishes a more accessible route for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. Its differentiated monolayers contain intestinal epithelial cell types, including enterocytes with cytochrome P450 and transporter activities, making the platform relevant to human pharmacokinetic studies while still requiring enzyme-specific validation.

• Carbapenemase Gene Transmission in CREC

  2026-09-07

  A 2025 BMC Microbiology study mapped carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals, combining gene localization, conjugation, mobile-element analysis, and strain typing. Its findings show that blaNDM-1 was frequently plasmid-associated and readily transferable in vitro, highlighting the need to interpret resistance surveillance through both clonal and horizontal-transmission frameworks.

• Cefoperazone Sodium Salt: Research Workflows

  2026-09-07

  Cefoperazone sodium salt supports reproducible susceptibility testing, β-lactamase-resistance studies, and PK-informed biliary tract infection research. This guide translates comparative microbiology into practical formulation, assay-design, and troubleshooting decisions.

7959 records 1/531 page Next 12345 下5页 Last page